Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.
The natural history of fibrosis development in hepatitis C is highly variable. Host, hepatic and viral factors have all been reported to influence the rate of fibrosis progression. An understanding of these factors is particularly important in the management of patients with mild disease, where treatment should be tailored to their personal risk of progression to cirrhosis.
Lawson
Adam
A
Wolfson Digestive Diseases Centre, Queen's Medical Centre, University of Nottingham, UK.
Ryder
Stephen D
SD
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000150:complications; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons